The observed drop in the Firmicutes/Bacteroidetes ratio after age 70 represents an adaptive host response that attempts to rebuild the anaerobic lumen by boosting colonocyte butyrate oxidation. This hypothesis predicts that activation of peroxisome proliferator‑activated receptor alpha (PPARα) in aged colonic epithelial cells increases fatty acid β‑oxidation, thereby consuming luminal oxygen and recreating the low‑oxygen niche favored by obligate anaerobic butyrate producers. Restoration of this oxygen gradient should suppress facultative anaerobes and Gammaproteobacteria, raise the F/B ratio toward youthful levels, and improve barrier function.

Butyrate normally supplies 70‑80% of colonocyte ATP through mitochondrial β‑oxidation, a process that directly consumes oxygen and maintains a serosal‑to‑luminal O2 gradient that keeps the lumen anaerobic [https://pmc.ncbi.nlm.nih.gov/articles/PMC8002420/]. Age‑related loss of butyrate‑producing microbes reduces this oxidative flux, leading to colonocyte energy deficit, AMPK activation, and a breakdown of the oxygen barrier that permits oxygen‑tolerant pathobionts to expand [https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1452917/full]. PPARα agonists are known to upregulate genes involved in fatty acid transport and β‑oxidation, enhancing mitochondrial respiration without necessarily increasing mitochondrial mass. By pharmacologically stimulating PPARα in aged colonocytes, we can compensate for the microbial deficit in butyrate supply, increase oxygen consumption, and thereby force the lumen back into an anaerobic state.

If this mechanism operates, three primary predictions follow: (1) Aged mice treated with a PPARα agonist (e.g., fenofibrate) will show higher colonocyte oxygen consumption rates measured by ex vivo Seebeck assay compared with vehicle controls. (2) Treated animals will exhibit a restored serosal‑to‑luminal oxygen gradient, detectable via intraluminal oxygen‑sensing probes, and a corresponding increase in luminal anaerobicity. (3) Concomitantly, fecal 16S rRNA sequencing will reveal a significant rise in the Firmicutes/Bacteroidetes ratio, particularly an expansion of butyrate‑generating families such as Lachnospiraceae and Ruminococcaceae, alongside a reduction in Enterobacteriaceae. These shifts should be accompanied by improved mucus thickness (via FFAR2/3 signaling) and decreased serum LPS, IL‑6, and TNF levels.

To test the hypothesis, we propose a longitudinal study in 24‑month‑old C57BL/6 mice. Animals will receive either fenofibrate (100 mg/kg/day) or control chow for eight weeks. Primary outcomes will include colonocyte respirometry (oxygen consumption normalized to protein), luminal O2 profiling, mucin layer thickness (histology with Alcian blue), barrier integrity (FITC‑dextran permeability assay), inflammatory cytokines (ELISA), and microbiome composition (16S sequencing). A secondary arm will transplant feces from treated donors into germ‑free young recipients to assess whether the metabolic state of the epithelium, rather than the microbiota alone, can transmit the protective phenotype.

Falsifiability is built in: if PPARα activation fails to raise colonocyte oxygen consumption, does not alter the luminal O2 gradient, or does not shift the F/B ratio despite adequate drug exposure, the hypothesis would be refuted. Likewise, if microbiota transfer from treated donors does not confer improved barrier function to young recipients, it would suggest that epithelial metabolic changes are insufficient to drive the observed compositional shifts, pointing instead to a primary microbial driver. This framework directly links host energetics to microbial ecology and offers a clear, measurable route to reverse age‑related gut barrier dysfunction.